Pyridine derivatives as inhibitors of REARRANGE DDURING TRANSACTION (RET) kinase

摘要

The present invention relates to novel compounds that are inhibitors of Rearranged during Transfection (RET) kinases, pharmaceutical compositions containing them, methods for their production, and gastrointestinal hypersensitivity, motility and / or secretion and / or abdomen. Normalization of disorder or disease, and / or RET dysfunction, but not limited to, diarrhea type, constipation type or alternating defecation pattern, functional bloating, functional constipation, functional diarrhea, Unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorder, functional gastroduodenal disorder, functional anorectal pain, irritable bowel syndrome (IBS) including inflammatory bowel disease; Small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, undifferentiated thyroid cancer, papillary thyroid cancer, brain tumor, abdominal cancer, solid tumor, other lung cancer, head and neck cancer, nerve , Neuroblastoma, von Hippel-Lindau syndrome and kidney tumor, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell carcinoma, prostate cancer, cancer of the esophagus and gastroesophageal junction, bile duct cancer, adenocarcinoma, and high RET kinase It relates to their use in monotherapy or combination therapy for the treatment of diseases where modulation of RET activity may have therapeutic benefit, including all classifications of proliferative diseases such as any malignant tumor with activity.